Response Biomedical (RPBIF) 0.5160 $RPBIF
Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China
ChinaBio Today - Seeking Alpha - 51 mins ago
Deals and Financings Cellular Biomedicine Group (NASDAQ: CBMG ), a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing (see story ). The two groups will...
NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), QGEN: 23.68 (-0.06), CBMG: 24.32 (-1.17)
Response Biomedical Corp. Announces Expansion of Chinese Distribution Agreement for RAMP(R) Cardiovascular Products
Marketwired - Fri Feb 06, 5:56PM CST
Response Biomedical Corp. ("Response" or the "Company"
(TSX: RBM)(OTCQB: RPBIF) today announced that it has expanded the scope of its agreement to distribute its Cardiovascular portfolio of RAMP(R) products with Shanghai Elite Biotech Co., Ltd. ("Shanghai Elite" . Effective April 23, 2015, Shanghai Elite will become the exclusive national distributor in China for Response's RAMP(R) branded cardiovascular Point of Care Testing ("POCT" portfolio.
RBM.TO: 0.75 (unch)
Response Biomedical Corp. Renegotiates Term Loan with Silicon Valley Bank
Marketwired - Mon Dec 15, 4:23PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCBB: RPBIF) announced that the Company has entered into an Amendment to its existing Loan Agreement (the "Amended Loan Agreement" with the lender under its outstanding term loan, Silicon Valley Bank ("SVB" , as of December 15, 2014. Under the terms of the Amended Loan Agreement, SVB has agreed to continue to advance the remaining outstanding principal of US$1,359,375 for the same term and interest rate, waive its rights in respect of the previously announced breaches of certain financial covenants and to remove any future minimum revenue and liquidity ratio financial covenants. SVB will receive additional warrants and a final payment of up to 4% of the principal advanced.
RBM.TO: 0.75 (unch)
Response Biomedical Corp. Announces Closing of Private Placement
Marketwired - Fri Dec 12, 12:49PM CST
Response Biomedical Corp. ("Response" or the "Company" (TSX: RBM)(OTCBB: RPBIF) is pleased to announce the closing of the previously announced non-brokered private placement (the "Private Placement" with two entities related to Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar" for 1,800,000 common shares of Response at a price of $1.21 per share for total gross proceeds of $2,178,000.
RBM.TO: 0.75 (unch)
Response Biomedical Corp. Announces Third Quarter 2014 Financial Results
Marketwired - Mon Nov 10, 4:01PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCBB: RPBIF) today reported financial results for the third quarter and nine months ended September 30, 2014 including a 5% increase in sales compared with the same period last year.
RBM.TO: 0.75 (unch)
Response Biomedical Corp. Schedules Third Quarter 2014 Earnings Release and Conference Call
Marketwired - Tue Nov 04, 4:38PM CST
Response Biomedical Corp. ("Response" (TSX: RBM)(OTCBB: RPBIF) will release its third quarter 2014 financial results after the markets close on Monday, November 10, 2014.
RBM.TO: 0.75 (unch)
Response Biomedical Corp. Provides Update on Term Loan
Marketwired - Mon Nov 03, 5:18AM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCBB: RPBIF) announced that the Company has entered into a second Forbearance to Loan Agreement (the "Forbearance Agreement" with the lender under its outstanding term loan, Silicon Valley Bank ("SVB" , as of October 31, 2014. Under the terms of the Forbearance Agreement, SVB will grant a forbearance under which it will agree not to exercise its rights in respect of a breach or an anticipated breach of a financial covenant under the terms of the loan agreement (the "Loan Agreement" until December 15, 2014.
RBM.TO: 0.75 (unch)
Response Biomedical Corp. Announces Funded Program and Equity Investment by Leading Chinese Medical Device Company
Marketwired - Wed Oct 15, 4:06PM CDT
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCBB: RPBIF) today announced that it has entered into a funded Technology Development Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar" to support the co-development by Response and Joinstar of components and multiple assays that will run on a high throughput rapid immunoassay analyzer developed by Joinstar. Under the terms of the Technology Development Agreement and related agreements, Response will receive cash proceeds totaling approximately $8.82 million. The parties have also entered into a binding term sheet for a definitive Supply Agreement whereby Response will provide certain raw materials to Joinstar required for Joinstar to manufacture these multiple assays.
RBM.TO: 0.75 (unch)
Response Biomedical Corp. Announces Government of Canada Funding to Support the Development of a New Sepsis Biomarker Test
Marketwired - Fri Oct 10, 1:46PM CDT
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCBB: RPBIF) today announced that it has entered into a funding agreement with the National Research Council of Canada Industrial Research Assistance Program ("NRC-IRAP" for up to $412,000 to support the development by Response of a new sepsis biomarker test for use on Response's RAMP(R) test platform. This new marker will complement Response's current cardiovascular and infectious disease test menu. Response believes that the development of this test will enable the Company to successfully expand its sales to its current RAMP(R) instrument customer base and also to help penetrate new markets.
RBM.TO: 0.75 (unch)
Response Biomedical Corp. Announces Management Changes
Marketwire - Tue Sep 16, 4:01PM CDT
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCBB: RPBIF) announced today a series of management changes. Jeffrey Purvin has resigned from the Board of Directors and as the President and Chief Executive Officer of the Company effective immediately. He will be succeeded as CEO by interim CEO Dr. Anthony "Tony" Holler, M.D., a long time Response Board member. In addition, Dr. Barbara Kinnaird, PhD., has been promoted from Vice President to Chief Operating Officer.
RBM.TO: 0.75 (unch)
Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China
ChinaBio Today - Seeking Alpha - 51 mins ago
Deals and Financings Cellular Biomedicine Group (NASDAQ: CBMG ), a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing (see story ). The two groups will...
NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), QGEN: 23.68 (-0.06), CBMG: 24.32 (-1.17)
Response Biomedical Corp. Announces Expansion of Chinese Distribution Agreement for RAMP(R) Cardiovascular Products
Marketwired - Fri Feb 06, 5:56PM CST
Response Biomedical Corp. ("Response" or the "Company"
(TSX: RBM)(OTCQB: RPBIF) today announced that it has expanded the scope of its agreement to distribute its Cardiovascular portfolio of RAMP(R) products with Shanghai Elite Biotech Co., Ltd. ("Shanghai Elite" . Effective April 23, 2015, Shanghai Elite will become the exclusive national distributor in China for Response's RAMP(R) branded cardiovascular Point of Care Testing ("POCT" portfolio. RBM.TO: 0.75 (unch)
Response Biomedical Corp. Renegotiates Term Loan with Silicon Valley Bank
Marketwired - Mon Dec 15, 4:23PM CST
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCBB: RPBIF) announced that the Company has entered into an Amendment to its existing Loan Agreement (the "Amended Loan Agreement" with the lender under its outstanding term loan, Silicon Valley Bank ("SVB" , as of December 15, 2014. Under the terms of the Amended Loan Agreement, SVB has agreed to continue to advance the remaining outstanding principal of US$1,359,375 for the same term and interest rate, waive its rights in respect of the previously announced breaches of certain financial covenants and to remove any future minimum revenue and liquidity ratio financial covenants. SVB will receive additional warrants and a final payment of up to 4% of the principal advanced. RBM.TO: 0.75 (unch)
Response Biomedical Corp. Announces Closing of Private Placement
Marketwired - Fri Dec 12, 12:49PM CST
Response Biomedical Corp. ("Response" or the "Company"
(TSX: RBM)(OTCBB: RPBIF) is pleased to announce the closing of the previously announced non-brokered private placement (the "Private Placement" with two entities related to Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar" for 1,800,000 common shares of Response at a price of $1.21 per share for total gross proceeds of $2,178,000. RBM.TO: 0.75 (unch)
Response Biomedical Corp. Announces Third Quarter 2014 Financial Results
Marketwired - Mon Nov 10, 4:01PM CST
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCBB: RPBIF) today reported financial results for the third quarter and nine months ended September 30, 2014 including a 5% increase in sales compared with the same period last year. RBM.TO: 0.75 (unch)
Response Biomedical Corp. Schedules Third Quarter 2014 Earnings Release and Conference Call
Marketwired - Tue Nov 04, 4:38PM CST
Response Biomedical Corp. ("Response"
(TSX: RBM)(OTCBB: RPBIF) will release its third quarter 2014 financial results after the markets close on Monday, November 10, 2014. RBM.TO: 0.75 (unch)
Response Biomedical Corp. Provides Update on Term Loan
Marketwired - Mon Nov 03, 5:18AM CST
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCBB: RPBIF) announced that the Company has entered into a second Forbearance to Loan Agreement (the "Forbearance Agreement" with the lender under its outstanding term loan, Silicon Valley Bank ("SVB" , as of October 31, 2014. Under the terms of the Forbearance Agreement, SVB will grant a forbearance under which it will agree not to exercise its rights in respect of a breach or an anticipated breach of a financial covenant under the terms of the loan agreement (the "Loan Agreement" until December 15, 2014. RBM.TO: 0.75 (unch)
Response Biomedical Corp. Announces Funded Program and Equity Investment by Leading Chinese Medical Device Company
Marketwired - Wed Oct 15, 4:06PM CDT
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCBB: RPBIF) today announced that it has entered into a funded Technology Development Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar" to support the co-development by Response and Joinstar of components and multiple assays that will run on a high throughput rapid immunoassay analyzer developed by Joinstar. Under the terms of the Technology Development Agreement and related agreements, Response will receive cash proceeds totaling approximately $8.82 million. The parties have also entered into a binding term sheet for a definitive Supply Agreement whereby Response will provide certain raw materials to Joinstar required for Joinstar to manufacture these multiple assays. RBM.TO: 0.75 (unch)
Response Biomedical Corp. Announces Government of Canada Funding to Support the Development of a New Sepsis Biomarker Test
Marketwired - Fri Oct 10, 1:46PM CDT
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCBB: RPBIF) today announced that it has entered into a funding agreement with the National Research Council of Canada Industrial Research Assistance Program ("NRC-IRAP" for up to $412,000 to support the development by Response of a new sepsis biomarker test for use on Response's RAMP(R) test platform. This new marker will complement Response's current cardiovascular and infectious disease test menu. Response believes that the development of this test will enable the Company to successfully expand its sales to its current RAMP(R) instrument customer base and also to help penetrate new markets. RBM.TO: 0.75 (unch)
Response Biomedical Corp. Announces Management Changes
Marketwire - Tue Sep 16, 4:01PM CDT
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCBB: RPBIF) announced today a series of management changes. Jeffrey Purvin has resigned from the Board of Directors and as the President and Chief Executive Officer of the Company effective immediately. He will be succeeded as CEO by interim CEO Dr. Anthony "Tony" Holler, M.D., a long time Response Board member. In addition, Dr. Barbara Kinnaird, PhD., has been promoted from Vice President to Chief Operating Officer. RBM.TO: 0.75 (unch)
